SCHEMBL374573

SCHEMBL374573

[CH2]CCN1CCCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1219977 0.93 L3MBTL1 (0.46) —
SCHEMBL1935110 0.91 L3MBTL1 (0.49) —
SCHEMBL2323038 0.87 PIK3CD (0.47) —
SCHEMBL261644 0.85 PIK3CD (0.58) —
SCHEMBL510427 0.81 — —
SCHEMBL5424673 0.81 PIK3CD (0.54) —
SCHEMBL3762707 0.81 L3MBTL1 (0.43) —
SCHEMBL9730913 0.79 L3MBTL1 (0.46) —
SCHEMBL19514132 0.79 PIK3CD (0.52) —
SCHEMBL729385 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1055 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023217764-A1 NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2023-11-16 — — WO claimed
CN-112457670-B Hydrophobic polyphenylene sulfide composition with high CTI (comparative tracking index) as well as preparation method and application thereof 金发科技股份有限公司 2022-05-10 — — CN claimed
CN-110982281-B Blended fluorosilicone rubber composition and preparation method thereof 福建拓烯新材料科技有限公司 2022-03-11 — — CN claimed
US-20210330678-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-28 — — US claimed
EP-3846808-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2021-07-14 — — EP claimed
US-20210177811-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2021-06-17 — — US claimed
EP-3703747-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER GenKyoTex Suisse SA (CH) 2020-09-09 — — EP claimed
CN-111344013-A Use of NOX inhibitors for the treatment of cancer 吉恩基奥泰克斯瑞士股份有限公司 2020-06-26 — — CN claimed
CN-110982281-A Blended fluorosilicone rubber composition and preparation method thereof 福建拓烯新材料科技有限公司 2020-04-10 — — CN claimed
EP-3479843-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER GenKyoTex Suisse SA (CH) 2019-05-08 — — EP claimed
EP-0274259-B1 New renin-inhibitory oligopeptides, their preparaton and their use SANKYO CO (JP) 1994-02-16 — — EP claimed
WO-1994002447-A1 HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1994-02-03 — — WO claimed
WO-1994002446-A1 NATURAL AMINO ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1994-02-03 — — WO claimed
US-5061725-A COGNITION ACTIVATORS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1991-10-29 — — US claimed
EP-0225866-B1 QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE Gerot-Pharmazeutika Gesellschaft m.b.H. (AT) 1991-09-25 — — EP claimed
EP-0408524-A1 (Pyrrolidin-2-on-l-yl) acetamides as enhancers of learning and memory and pharmaceutical compositions comprising same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1991-01-16 — — EP claimed
US-4818754-A ANTIALLERGENS BEECHAM GROUP P.L.C. OF BEECHAM HOUSE (GB) 1989-04-04 — — US claimed
EP-0274259-A2 New renin-inhibitory oligopeptides, their preparaton and their use Sankyo Company Limited (JP) 1988-07-13 — — EP claimed
EP-0243055-A2 Pyrazolopyridine derivatives, process for their preparation, and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1987-10-28 — — EP claimed
EP-0230242-A2 Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1987-07-29 — — EP claimed
Send feedback